Proactive Investors UKAmryt Pharmaceuticals PLC licenses gene therapy platform from …Proactive Investors UKAmryt Pharma PLC (LON:AMYT) has licensed a non-viral gene therapy platform technology with potential applicability across a range of genetic di… Continue reading
|
Global Synthetic Biology Market Till 2024 Research Report | DecisionDatabases
Investor Opinion Synthetic Biology Market Report added by DecisionDatabases.com offers industry size, share, growth, trends and forecast analysis upto 2024. Synthetic Biology Market Report also covers top key players, porter’s five forces analysis and market … |
Siliconrepublic.com |
Irish biopharma company and UCD to use gene therapy for rare skin disorder
Siliconrepublic.com With the aim of developing a treatment for a rare and debilitating skin disorder, an Irish biopharma company and UCD have signed a gene therapy licencing deal. Amryt, the Irish-listed biopharma company that focuses on rare and so-called ‘orphan … Amryt licenses gene therapy platform; refines its Phase III EASE study of AP101Proactive Investors UK Amryt reports strong 2017 as revenues rise to almost €13mIrish Times Irish company focused on bad cholesterol treatment sees revenue increase to €13mIndependent.ie |